Items tagged with Drug-resistant TB
HIV infection may be driving drug resistance in TB (post)
Results published recently in The Lancet Microbe detail analysis of 10 years’ health data, showing a relationship between HIV infection and acquisition of rifampicin resistance by tuberculosis (TB). Rifampicin is an important first‑line anti‑TB medication.
Webinar series: Building our toolkit for local TB elimination (post)
The Center for Global Health, branch of the organization Socios En Salud | Partners In Health Peru, will host a series of webinars on diagnosis and treatment for drug-resistant TB as part of the Zero Tuberculosis Initiative, a multi-institutional alliance of local coalitions working to rapidly reduce TB rates by using a comprehensive approach.
RESIST-TB webinar on NeXT clinical trial (post)
On 23 September 2021, RESIST-TB will host a webinar to present the results of the recently-completed NeXT clinical trial for multidrug-resistant TB.
RESIST-TB August 2021 newsletter (post)
RESIST-TB released its August 2021 newsletter with the latest research publications on drug-resistant TB.
TB Alliance: Community engagement virtual forum - recording now available online (post)
On 12 August 2021, TB Alliance hosted a public webinar for community stakeholders to share details of the recently announced results from the ZeNix Phase 3 clinical trial. The trial revealed that the 6-month BPaL treatment regimen (bedaquiline, pretomanid and linezolid) remains effective against highly drug-resistant strains of TB with either reduced dosage or duration of the linezolid component of the regimen. Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.
TB Alliance and Lupin announce commercial partnership for new therapy for highly drug-resistant TB (post)
Agreement between non-profit product development partnership and multinational pharmaceutical company will expand access to new TB drug.
RESIST-TB September 2021 newsletter (post)
RESIST-TB released its September 2021 newsletter with the latest research publications on drug-resistant TB.
Hear us! Accounts of people treated with injectables for drug-resistant TB (post)
An article published in Public Health Action features testimonials from 14 TB survivors in 12 countries regarding their experiences with hearing loss from injectable-containing treatment regimens for drug-resistant TB.
Largest ever global TB study identifies genetic causes of drug resistance (post)
Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common TB drug treatments.
EndTB clinical trial for multidrug-resistant TB completes enrolment (post)
BOSTON/PARIS, 18 October 2021 — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Médecins Sans Frontières (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD) make up the endTB consortium conducting the groundbreaking study funded by Unitaid.
Page 71 of 117 · Total posts: 0
←First 70 71 72 Last→